65,033 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 65,033 shares of the company’s stock, valued at approximately $1,894,000.

A number of other hedge funds have also recently modified their holdings of DNLI. Pier Capital LLC lifted its position in Denali Therapeutics by 1.6% during the 3rd quarter. Pier Capital LLC now owns 168,082 shares of the company’s stock valued at $4,896,000 after acquiring an additional 2,596 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Denali Therapeutics by 9.2% during the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after purchasing an additional 903,683 shares during the last quarter. Polar Asset Management Partners Inc. lifted its holdings in shares of Denali Therapeutics by 70.5% during the third quarter. Polar Asset Management Partners Inc. now owns 41,100 shares of the company’s stock valued at $1,197,000 after purchasing an additional 17,000 shares during the last quarter. Holocene Advisors LP boosted its position in shares of Denali Therapeutics by 65.0% in the 3rd quarter. Holocene Advisors LP now owns 97,447 shares of the company’s stock worth $2,839,000 after purchasing an additional 38,405 shares in the last quarter. Finally, Cinctive Capital Management LP grew its stake in shares of Denali Therapeutics by 32.7% in the 3rd quarter. Cinctive Capital Management LP now owns 149,094 shares of the company’s stock worth $4,343,000 after buying an additional 36,771 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Trading Down 2.1 %

NASDAQ:DNLI opened at $22.97 on Friday. The company has a 50 day simple moving average of $26.28 and a two-hundred day simple moving average of $24.80. The company has a market cap of $3.31 billion, a PE ratio of -8.32 and a beta of 1.35. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the prior year, the firm posted ($0.72) earnings per share. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on DNLI. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Denali Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald downgraded shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Jefferies Financial Group lifted their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. JPMorgan Chase & Co. cut their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Bank of America boosted their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.90.

Insider Activity

In other news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. The trade was a 50.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Vicki L. Sato sold 1,020 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,578 shares of company stock valued at $2,474,440 in the last quarter. 7.90% of the stock is currently owned by insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.